Skip to main content

NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.

Publication ,  Journal Article
Griffiths, EA; Roy, V; Alwan, L; Bachiashvili, K; Baird, J; Cool, R; Dinner, S; Geyer, M; Glaspy, J; Gojo, I; Hicks, A; Kallam, A; Kidwai, WZ ...
Published in: J Natl Compr Canc Netw
May 2022

The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

May 2022

Volume

20

Issue

5

Start / End Page

436 / 442

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Hematopoietic Cell Growth Factors
  • Antineoplastic Agents
  • Anemia
  • Adult
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Griffiths, E. A., Roy, V., Alwan, L., Bachiashvili, K., Baird, J., Cool, R., … Pluchino, L. (2022). NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. J Natl Compr Canc Netw, 20(5), 436–442. https://doi.org/10.6004/jnccn.2022.0026
Griffiths, Elizabeth A., Vivek Roy, Laura Alwan, Kimo Bachiashvili, John Baird, Rita Cool, Shira Dinner, et al. “NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.J Natl Compr Canc Netw 20, no. 5 (May 2022): 436–42. https://doi.org/10.6004/jnccn.2022.0026.
Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, et al. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. J Natl Compr Canc Netw. 2022 May;20(5):436–42.
Griffiths, Elizabeth A., et al. “NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.J Natl Compr Canc Netw, vol. 20, no. 5, May 2022, pp. 436–42. Pubmed, doi:10.6004/jnccn.2022.0026.
Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar V, Patel S, Perez LE, Poust A, Riaz F, Rosovsky R, Rugo HS, Simon S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Berardi RA, Pluchino L. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. J Natl Compr Canc Netw. 2022 May;20(5):436–442.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

May 2022

Volume

20

Issue

5

Start / End Page

436 / 442

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Hematopoietic Cell Growth Factors
  • Antineoplastic Agents
  • Anemia
  • Adult
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis